Shozo Ogawa
Internal Medicine · Honolulu, HINPI 1477655116
Payments from drug & device makers
Across 144 payments — averaging $52.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$865
- Sanofi-aventis U.S. LLC$617
- Abbott$569
- plus $2K from 11 others
What the payments were for
- Food & beverage$7,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $1,395 |
| Lilly USA, LLC | 27 | $1,151 |
| Novo Nordisk | 22 | $1,016 |
| AstraZeneca | 15 | $865 |
| Sanofi-aventis U.S. LLC | 23 | $617 |
| Abbott | 9 | $569 |
| Bayer | 5 | $409 |
| AbbVie | 5 | $309 |
| Boehringer Ingelheim | 3 | $285 |
| Astellas Pharma US Inc | 3 | $231 |
| Merck | 2 | $149 |
| Insulet Corporation | 1 | $141 |
| Sunovion Pharmaceuticals Inc. | 1 | $125 |
| Dexcom, Inc. | 1 | $122 |
| Amarin Pharma, Inc. | 1 | $60 |
| Johnson & Johnson | 1 | $34 |
| GSK | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$489
- EVENITY$478
- Ozempic$459
- FREESTYLE LIBRE 3$393
- Prolia$367
- Kerendia$361
- JARDIANCE$250
- TOUJEO$250
- MOUNJARO$224
- Repatha$222
- KRYSTEXXA$150
- Omnipod$141
- FreeStyle Libre 2$127
- MYRBETRIQ$125
- VRAYLAR$125
- QULIPTA$125
- UBRELVY$125
- SOLIQUA 100/33$125
- CAPVAXIVE$125
- LONHALA MAGNAIR$125
How this compares
$7,496 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 19 | $2,387 |
| Amlodipine Besylate | 66 | $838 |
| Atorvastatin Calcium | 32 | $693 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $538 |
| Simvastatin | 17 | $362 |
| Allopurinol | 26 | $309 |
| Lisinopril | 17 | $135 |
| Metformin Hcl | 20 | $131 |
| Glimepiride | 12 | $125 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Honolulu
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
- Anthony HernandezHonolulu$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.